Vertex Reports Third Quarter 2024 Financial Results

Sep 30, 2024 · To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2024 Earnings Call.” …

CouponFollow Extension

$10
OFF

Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call …

3 weeks from now

Nov 5, 2024 · The company increased its full-year product revenue guidance to $10.8 billion to $10.9 billion, reflecting strong growth and performance. Vertex Pharmaceuticals Inc …

yahoo.com

6%
OFF

Vertex Pharmaceuticals Reports Strong Q3 Earnings, Surpassing ...

3 weeks from now

Nov 6, 2024 · Vertex Pharmaceuticals has demonstrated impressive financial resilience with a Q3 profit of $1.045 billion and an 11.6% revenue increase, even amidst market fluctuations. ...

folikoinsights.com

6%
OFF

Vertex Pharmaceuticals Reports Strong Q3 Revenue Growth Amid …

3 weeks from now

Jan 18, 2025 · Vertex Pharmaceuticals showcases resilience with an impressive 11.6% revenue growth in Q3 2024, despite facing stock challenges. As the FDA decision on suzetrigine …

folikoinsights.com

6%
OFF

Vertex Pharmaceuticals Reports Strong Q3 Revenue Growth Amid …

3 weeks from now

Jan 10, 2025 · Vertex Pharmaceuticals showcases impressive Q3 results with an 11.6% revenue increase, yet faces stock volatility and skepticism around its pain medication. As the company …

folikoinsights.com

12%
OFF

Vertex Pharmaceuticals Q3 Revenue Rises By 12% - VRTX

3 weeks from now

Vertex Pharmaceuticals reported a strong Q3 2024, with revenue increasing by 12% year-over-year to $2.77 billion. The company raised its full-year revenue guidance to between $10.8 …

investingsnacks.com

12%
OFF

Vertex Pharmaceuticals Reports Strong Q3 2024 Growth

3 weeks from now

Nov 5, 2024 · Vertex Pharmaceuticals has reported a significant financial performance in the third quarter of 2024, with a product revenue of $2.77 billion, marking a 12% increase compared to …

nasdaq.com

6%
OFF

Vertex Pharmaceuticals Inc (VRTX) Reports 6% Increase In Q3 2023 ...

3 weeks from now

Nov 6, 2023 · VRTX reported a 6% increase in Q3 2023 product revenue, reaching $2.48 billion. The company raised its full year 2023 product revenue guidance to approximately $9.85 billion.

yahoo.com

12%
OFF

Vertex Pharmaceuticals Inc (VRTX) Q3 2024 Earnings Call Highligh

3 weeks from now

Nov 5, 2024 · Revenue: $2.77 billion in Q3 2024, 12% growth compared to Q3 2023.Full-Year Revenue Guidance: Increased to $10.8 billion to $10.9 billion.Non-GAAP Operating In. Vertex …

gurufocus.com

$4.38
OFF

Vertex Pharmaceuticals (VRTX) Q3 Earnings And Revenues Top …

3 weeks from now

Nov 4, 2024 · Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings …

yahoo.com

$4.38
OFF

Vertex Pharmaceuticals Reports Q3 Adjusted EPS $4.38, Consensus …

3 weeks from now

Nov 4, 2024 · Reports Q3 revenue $2.77B, consensus $2.72B. “The third quarter marked another period of strong progress, with continued revenue growth an...

businessinsider.com

12%
OFF

Vertex Reports Third Quarter 2024 Financial Results

3 weeks from now

Nov 4, 2024 · Vertex Pharmaceuticals reported strong Q3 2024 results with product revenue of $2.77 billion, up 12% year-over-year.The company raised its full-year 2024 product revenue …

stocktitan.net

$2.77
OFF

Vertex Pharmaceuticals Reports Strong Q3 Earnings As Stock …

3 weeks from now

Nov 10, 2024 · Vertex Pharmaceuticals has showcased impressive Q3 results, with net revenues hitting $2.77 billion and a raised full-year forecast, driven by its leading cystic fibrosis …

folikoinsights.com

06%
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Poised For Growth …

3 weeks from now

Strong Financial Performance and Market Position. Vertex has demonstrated robust financial health, with revenue growing 10.06% over the last twelve months to $10.6 billion.

msn.com

$10
OFF

Vertex Pharmaceuticals' Next Big Chapter? Vertex Stock Surges On ...

3 weeks from now

2 days ago · Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped. The company won Food and Drug …

investors.com

FAQs about Vertex Reports Third Quarter 2024 Financial Results Coupon?

How did Vertex Pharmaceuticals (VRTX) perform in Q3 2023?

Vertex Pharmaceuticals Inc ( NASDAQ:VRTX) released its earnings report for the third quarter ended September 30, 2023, on November 6, 2023. The company reported a 6% increase in product revenue, reaching $2.48 billion, primarily driven by the continued performance of TRIKAFTA in the U.S. and strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets. ...

What did Vertex Pharmaceuticals (VRTX) report?

BOSTON -- (BUSINESS WIRE)--Nov. 6, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2023, raised full year 2023 guidance for product revenue and reiterated full year 2023 guidance for operating expenses. ...

What is vertex's financial guidance for 2024?

Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion. Vertex’s product revenue guidance includes expectations for continued growth in CF as well as for the launch of CASGEVY in approved indications and geographies. ...

Is Vertex Pharmaceuticals a good stock to buy in 2025?

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. ...

Is vertex a good stock to buy in 2024?

Vertex appears quite expensive at 900x earnings estimates for 2024, which will become trailing earnings once the company releases its Q4 results on February 10. However, 2024 earnings are greatly impacted by the expense of multiple Phase 3 clinical trials, in addition to the acquisition of Alpine Immune Sciences for $4.9 billion in cash last year. ...

Should you buy vertex Pharmaceutical Inc (VRTX)?

With multiple ongoing clinical trials and a robust pipeline, Vertex is poised to exceed conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share. Last November, I initiated coverage on Vertex Pharmaceutical Inc. (NASDAQ: VRTX) suggesting the stock as a strong buy around $461/share. ...